While not directly related to CLL, this second FDA approved indication is another reason to anticipate that zanubrutinib will soon be an approved option for chronic lymphocytic leukemia (CLL) patients. And that is good news for us. The more treatment choices we have, the better.
January 31, 2023
BREAKING NEWS
Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Menu
